BioSpace News Archive

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd., a subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd., signed a licensing agreement with Austria-based Marinomed Biotech AG, whereby Shandong Luoxin will gain the exclusive rights for the development, manufacture, and commercialization of Budesolv® in China.

Mentice AB announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Gunilla Andersson.

Antengene Corporation Limited announced that it has entered into a Research Collaboration and License Option Agreement with LegoChem Biosciences, Inc. for new antibody-drug conjugates.

United Therapeutics Corporation, a public benefit corporation with a purpose to provide a brighter future for patients, detailed the new clinical and real-world evidence on pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease presented at CHEST 2021, the annual meeting of the American College of Chest Physicians.

Danaher Corporation announced results for the third quarter 2021. All results in this release reflect only continuing operations unless otherwise noted.

Pfizer Inc. and BioNTech SE announced topline results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine in more than 10,000 individuals 16 years of age and older.

reMYND NV, a clinical stage company, is pleased to announce that it has initiated the multiple-ascending-dose (MAD) phase of its Alzheimer’s program after observing no compound-related ReS19-T adverse events so far in the 58 healthy volunteers in the single-ascending dose (SAD) phase.

Evelo Biosciences, Inc. today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, October 28, 2021, to report its third quarter 2021 financial results and discuss business highlights.

Matinas BioPharma Holdings, Inc. today announced that it has dosed the first patient in a Phase 1 single ascending dose (SAD) pharmacokinetic study in healthy volunteers with MAT2501.

NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2021.